Okairos AG

Elisabethenstrasse 3,
Basel, 4051
Switzerland,
+41 61 270 35 35
www.okairos.com

Okairos - is a non-listed clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, HIV, respiratory syncytial virus and cancer - using a novel proprietary technology. The company is also pursuing therapeutic vaccines to treat cancer.

Okairos AG was acquired by GlaxoSmithKline on May 29, 2013.

Join Mergr to view all 175 acquisitions of life science companies in 2013, including 20 acquisitions by private equity firms, and 155 by strategics.

Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.

Join Mergr to view this profile - and discover more life science acquisitions of companies like Okairos AG.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 112K M&A Transactions
  • 121K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.